Johnson & Johnson (JNJ) –
-
Midday movers: RH, Estee Lauder rise; Tesla falls
-
Johnson & Johnson (JNJ) option IV flat
-
J&J can contest evidence linking its talc to cancer, US judge rules
-
Johnson & Johnson (JNJ) Gets New Opp. to Contest Evidence Linking Talc to Cancer - Reuters
-
Midday movers: GameStop falls; Merck, Robinhood and Moderna rise
-
Form PX14A6G JOHNSON & JOHNSON Filed by: National Legal & Policy Center
-
Wells Fargo Reiterates Equal Weight Rating on Johnson & Johnson (JNJ), 'We see SWAV as potentially a good strategic fit'
-
After-hours movers: Merck, GameStop, Shockwave Medical, and more
-
Johnson & Johnson (JNJ) considers deal for Shockwave Medical (SWAV) - WSJ
-
J&J in talks to buy Shockwave Medical, WSJ reports
-
Johnson & Johnson (JNJ) Considers Deal to Acquire Shockwave Medical (SWAV) - WSJ
-
Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE™ Platform for the Treatment of Paroxysmal Atrial Fibrillation
-
Johnson & Johnson's (JNJ) Janssen Receives FDA Approval for Edurant
-
Johnson & Johnson (JNJ): FDA Advisers Unanimously Vote that carvykti Benefits Outweighing Risks as Earlier Treatment for a Type of Blood Cancer
-
Form 4 JOHNSON & JOHNSON For: Mar 13 Filed by: Broadhurst Vanessa
-
Form 144 JOHNSON & JOHNSON Filed by: Broadhurst Vanessa
-
US FDA staff raises concerns over data from J&J, Bristol's CAR-T therapies
-
Johnson & Johnson (JNJ): FDA Staff Reviewers: "Unclear Whether the Overall Benefit-risk Assessment is Favorable" for Carvykti
-
Form ARS JOHNSON & JOHNSON For: Dec 31
-
Form DEFA14A JOHNSON & JOHNSON
-
Form DEFA14A JOHNSON & JOHNSON
-
Form DEF 14A JOHNSON & JOHNSON For: Apr 25
-
Artelo Biosciences (ARTL) Picked as a Finalist in Johnson & Johnson’s (JNJ) Innovation Challenge
-
Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge
-
Johnson & Johnson (JNJ) Files sBLA for TREMFYA
-
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
-
Form 4 JOHNSON & JOHNSON For: Mar 05 Filed by: Woods Eugene A.
-
Form 4 JOHNSON & JOHNSON For: Mar 05 Filed by: HEWSON MARILLYN A
-
Johnson & Johnson (JNJ) Completes Acquisition of Ambrx
-
Johnson & Johnson Completes Acquisition of Ambrx
-
Ambrx (AMAM) Shareholders Approve Acquisition by Johnson & Johnson (JNJ)
-
Latest J&J talc trial ends with hung jury
-
Johnson & Johnson (JNJ) Announces FDA Approval of RYBREVANT + chemotherapy
-
RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutat
-
Johnson & Johnson (JNJ) receives positive EMA CHMP opinion for expanded label for Carvykti
-
Form 4 JOHNSON & JOHNSON For: Feb 15 Filed by: Taubert Jennifer L
-
Form 4 JOHNSON & JOHNSON For: Feb 15 Filed by: Wengel Kathryn E
-
Form 4 JOHNSON & JOHNSON For: Feb 15 Filed by: Hait William
-
Form 4 JOHNSON & JOHNSON For: Feb 15 Filed by: Schmid Timothy
-
Form 4 JOHNSON & JOHNSON For: Feb 15 Filed by: Swanson James D.
-
Form 4 JOHNSON & JOHNSON For: Feb 15 Filed by: Wolk Joseph J
-
Form 4 JOHNSON & JOHNSON For: Feb 15 Filed by: Broadhurst Vanessa
-
Form 4 JOHNSON & JOHNSON For: Feb 15 Filed by: Decker Robert J
-
Form 4 JOHNSON & JOHNSON For: Feb 15 Filed by: REED JOHN C
-
Form 4 JOHNSON & JOHNSON For: Feb 15 Filed by: Forminard Elizabeth
-
Form 4 JOHNSON & JOHNSON For: Feb 15 Filed by: Fasolo Peter
-
Form 4 JOHNSON & JOHNSON For: Feb 15 Filed by: Duato Joaquin
-
Johnson & Johnson (JNJ) Announces FDA Approval of TECVAYLI Biweekly Dosing
-
TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma
-
Form 10-K JOHNSON & JOHNSON For: Dec 31
Back to JNJ Stock Lookup